Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial

被引：0
|
作者：
de Wit, R. [1 ]
Kulkarni, G. S. [2 ]
Uchio, E. [3 ]
Singer, E. A. [4 ]
Krieger, L. [5 ]
Grivas, P. [6 ]
Bajorin, D. [7 ]
Seo, H. K. [8 ]
Mourey, L. [9 ]
Kamat, A. [10 ]
Nishiyama, H. [11 ]
Kapadia, E. [12 ]
Nam, K. [12 ]
Frenkl, T. [12 ]
Balar, A. [13 ]
机构：
[1] Erasmus MC, Med Oncol, Inst Canc, Rotterdam, Netherlands
[2] UHN Princess Margaret Canc Ctr, Surg & Surg Oncol, Toronto, ON, Canada
[3] UC Irvine Hlth, Urol, Orange, CA USA
[4] Rutgers Canc Inst New Jersey, Urol, New Brunswick, NJ USA
[5] Royal North Shore Hosp, Med Oncol, Northern Canc Inst, St Leonards, NSW, Australia
[6] Univ Washington, Fred Hutchinson Canc Res Ctr, Med Oncol, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[7] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[8] Natl Canc Ctr, Urol, Goyang, South Korea
[9] Inst Univ Canc Toulouse Oncopole, Med Oncol, Toulouse, France
[10] Univ Texas MD Anderson Canc Ctr, Urol, Houston, TX 77030 USA
[11] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan
[12] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[13] NYU Langone Med Ctr, Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
864O
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [41] HEALTHCARE RESOURCE USE (HCRU) OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS POST BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE STATUS IN MULTIPLE COUNTRIES
    Broughton, E.
    Chun, D.
    Gooden, K.
    Mycock, K.
    Rajkovic, I
    Taylor-Stokes, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S484 - S485
  • [42] Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer
    Sylvester, Richard J.
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (02) : 113 - 120
  • [43] Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guerin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer
    Joshi, Mrinmayee
    Atlas, Steven J.
    Beinfeld, Molly
    Chapman, Richard H.
    Rind, David M.
    Pearson, Steven D.
    Touchette, Daniel R.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : 823 - 832
  • [44] Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guerin failure
    Shantharam, Govind
    Amin, Ali
    Pereira, Jorge
    Kott, Ohad
    Mueller-Leonhard, Catrina
    Mega, Anthony
    Golijanin, Dragan
    Gershman, Boris
    [J]. CURRENT UROLOGY, 2021, 15 (01) : 33 - 38
  • [45] The Effectiveness of Bacillus Calmette-Guerin (BCG) Maintenance Treatment in Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Kim, B.
    Ha, J.
    Park, C.
    Kim, C.
    [J]. UROLOGY, 2012, 80 (03) : S215 - S216
  • [46] THE BURDEN OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AMONG PATIENTS TREATED WITH BACILLUS CALMETTE-GUERIN
    Kopenhafer, L.
    Chang, J.
    Thompson, A.
    Sikirica, S.
    Masters, E. T.
    Cappelleri, J. C.
    Peck, E. Y.
    Maculaitis, M. C.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S557 - S557
  • [47] Bacillus Calmette-Guerin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
    Steinberg, Ryan L.
    Thomas, Lewis J.
    O'Donnell, Michael A.
    [J]. BLADDER CANCER, 2015, 1 (02) : 105 - 116
  • [48] KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guerin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
    Shariat, S. F.
    Steinberg, G.
    Kamat, A. M.
    Shore, N. D.
    Alanee, S.
    Nishiyama, H.
    Nam, K.
    Godwin, J. L.
    Kapadia, E.
    Hahn, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S723 - S723
  • [49] Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
    Steinberg, Ryan L.
    Thomas, Lewis J.
    Mott, Sarah L.
    O'Donnell, Michael A.
    [J]. BLADDER CANCER, 2016, 2 (02) : 215 - 224
  • [50] TRIALS IN PROGRESS: A PHASE I/II TRIAL OF INTRAVESICAL CHEMOIMMUNOTHERAPY WITH GEMCITABINE AND BACILLUS CALMETTE-GUERIN (BCG) FOR PATIENTS WITH BCG-EXPOSED HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Gaffney, Christopher
    D'Souza, Neeta
    Hernandez, Christian
    McCarter, Melissa
    Moran, Patricia
    Staci, Kristen
    Worth, Kara
    Dalbagni, Guido
    Donahue, Timothy
    Donat, Sherri
    Bochner, Bernard
    Sarungbam, Judy
    Bajorin, Dean
    AL-Ahmadie, Hikmat
    Sjoberg, Daniel
    Goh, Alvin
    Pietzak, Eugene
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E876 - E876
12345